- $1.67bn
- $1.42bn
- $405.06m
- 87
- 20
- 73
- 61
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 263 | 297 | 359 | 399 | 405 |
Cost of Revenue | |||||
Gross Profit | 123 | 131 | 178 | 181 | 205 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 249 | 279 | 304 | 372 | 354 |
Operating Profit | 13.8 | 17.4 | 55.6 | 27.2 | 51.4 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 14.9 | 18.5 | 56.8 | 28.7 | 60.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | 14.1 | 17.9 | 56.6 | 25.4 | 53.6 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 14.1 | 17.9 | 56.6 | 25.4 | 53.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 14.1 | 17.9 | 56.6 | 25.4 | 53.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.337 | 0.408 | 1.26 | 0.695 | 1.19 |